Sana Biotechnology Inc (SANA) Noticias

SANA: FUNNY!! And it otherwise now appears that this Firm's former happy 'SANA-Claus" bearing gifts routine is DONE. (No puns intended.)

lol , jumping jack flash , sanitation engineer.

SANA: So, maybe now this is a classic 'SANA-tation' truck routine??? (No pun intended.)

in at $5.55 pre market... was gonna sell at $7.15 uhhh was....nope never got tooooo greedy lol im down but it will come back....news is tooooooooooo good!!!!

In at 5.75 pre market out at 6.49 fun ride ! 

maybe higher - the news is friggin huge

Short squeeze to $10.00

Made a quick low six digit profit here this morning in and out 12% gain

$SANA

Fluck, a posting glitch in the IHub algorithm!! (Right???)

SANA: 795-Followers STRONG, Bro!!! God-BLESS!!! (And I leave yah all tonight, with the greatest rock song of all TIME!!!)

SANA > a company focused on changing the possible for patients through engineered cells, today announced initial results from an investigator-sponsored, first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana’s hypoimmune (HIP) technology, into a patient with type 1 diabetes without the use of any immunosuppression. The study was conducted in partnership with Uppsala University Hospital. Results of the study at four weeks after cell transplantation demonstrate the survival and function of pancreatic beta cells as measured by the presence of circulating C-peptide, a biomarker indicating that transplanted beta cells are producing insulin. C-peptide levels also increase with a mixed meal tolerance test (MMTT), consistent with insulin secretion in response to a meal. MRI scanning also demonstrated a sustained signal at the site of transplanted cells over time, which is consistent with graft survival. The study identified no safety issues, and the HIP-modified islet cells evaded immune responses.
“These initial exciting results build upon the extensive preclinical and translational studies of Dr. Sonja Schrepfer and the team at Sana. The clinical data are highly promising for patients and provide the first evidence in humans for overcoming allogeneic and autoimmune rejection with pancreatic islet cell transplantation in type 1 diabetes with no immunosuppression,” said Per-Ola Carlsson, MD, Study Principal Investigator, Senior Physician and Professor at the Clinic for Endocrinology and Diabetology at Uppsala University Hospital. “In type 1 diabetes, a person’s immune system attacks and destroys the beta cells. Today’s data, when combined with progress elsewhere in the field, provide real hope that a scalable, curative treatment for patients with type 1 diabetes, meaning normal blood glucose with no insulin injections or immunosuppression, is possible. We look forward to longer follow-up and plan to submit study results for publication as well as for presentation at an upcoming scientific forum.”

SANA: THAT's how yah do it!!! (CONGRATS!!!) 'SANA Claus' came a little LATE on that one!!!

in at $4.90 out at $7.29 AH

Probably these programs want to hold some hostage. Casino must always win

SANA: What the heck will it do TOMORROW??? (Likely all over in the Post-M right here?)

InSANAty the cure is here $7 + 424%

SANA: 325% behind that Diabetes-news shocker!!

SANA: Nevertheless, this could very well be a 6-8 bagger tomorrow --- behind THAT kind of (Diabetes-related) news.

SANA: However, NO tiny float here, at 122-Million shares.

SANA, over $2

SANA: Just passed Planet Mars. (In-SANA-ty!!!!)

"Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression"
https://finance.yahoo.com/news/sana-biotechnology-announces-positive-clinical-210500452.html

SANA HUGE MOVE AFTER HOURS

SANA, under $2

SANA under $5

SANA under $7

SANA under $7

SANA under $10

SANA new 52 week high

SANA up from a low in November

https://www.globenewswire.com/news-release/2023/03/16/2629176/0/en/Sana-Biotechnology-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Business-Updates.html